Cargando…
Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer
The mutation of the crucial genes such as tumor suppressors or oncogenes plays an important role in the initiation and development of tumors. The non-synonymous mutations in the tumor cell genome will produce non-autologous proteins (neoantigen) to activate the immune system by activating CD4+ and C...
Autores principales: | Zhang, Xin, Xu, Zheng, Dai, Xiangpeng, Zhang, Xiaoling, Wang, Xueju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905145/ https://www.ncbi.nlm.nih.gov/pubmed/36761724 http://dx.doi.org/10.3389/fimmu.2023.1104860 |
Ejemplares similares
-
A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment
por: Chen, Zheling, et al.
Publicado: (2021) -
Designing neoantigen cancer vaccines, trials, and outcomes
por: Biswas, Nupur, et al.
Publicado: (2023) -
Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022) -
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
por: Wang, Luyao, et al.
Publicado: (2023) -
Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine
por: Morisaki, Shinji, et al.
Publicado: (2023)